Non-Small Cell Lung Cancer
Conditions
Interventions
Case series:None
Sponsors
Shanghai General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients with newly diagnosed primary stage III-IV non-small cell lung cancer (NSCLC) who are receiving aumolertinib monotherapy; 2. EGFR mutation-positive; 3. Aged >= 18 years; 4. ECOG PS score: 0 to 2 points; 5. Estimated survival time = 12 weeks, and patients are amenable to follow-up; 6. No concurrent chemotherapy, immunotherapy, radiotherapy, radiofrequency ablation, or other targeted agents were administered prior to or during treatment; 7. Presence of measurable disease per RECIST v1.1 (at least one target lesion).
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women; 2. Active bacterial, viral, or fungal diseases requiring treatment that are not controlled; 3. Concurrent other malignant tumors;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-Free Survival (PFS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse Event; | — |
Countries
China
Contacts
Public ContactXuefang Cheng
Shanghai General Hospital
Outcome results
None listed